İsrail - İbranice - Ministry of Health

takeda israel ltd - ixazomib as citrate - קפסולות - ixazomib as citrate 4 mg - ixazomib

İsrail - İbranice - Ministry of Health

lundbeck israel ltd. - nalmefene as hydrochloride dihydrate - טבליות מצופות פילם - nalmefene as hydrochloride dihydrate 18.06 mg - nalmefene

İsrail - İbranice - Ministry of Health

lundbeck israel ltd. - nalmefene as hydrochloride dihydrate - טבליות מצופות פילם - nalmefene as hydrochloride dihydrate 18.06 mg - nalmefene

İsrail - İbranice - Ministry of Health

lundbeck israel ltd. - escitalopram as oxalate - טבליות מצופות פילם - escitalopram as oxalate 10 mg - escitalopram

İsrail - İbranice - Ministry of Health

lundbeck israel ltd. - escitalopram as oxalate - טבליות מצופות פילם - escitalopram as oxalate 5 mg - escitalopram

İsrail - İbranice - Ministry of Health

trupharm marketing 1985 ltd. - dermatophagoides farina; dermatophagoides pteronyssinus - טבליה - dermatophagoides pteronyssinus 6 sq-hdm; dermatophagoides farina 6 sq-hdm - house dust

İsrail - İbranice - Ministry of Health

medison pharma ltd - interferon beta 1a - תמיסה להזרקה - interferon beta 1a 30 mcg / 0.5 ml - interferon beta-1a - interferon beta-1a - treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and to decrease the frequency of clinical exacerbations. treatment of patients who have experienced a single demyelinating event with an active inflammatory process if it is severe enough to warrant treatment with intravenous corticosteroids if alternative diagnosis have been excluded, including the prescence of mri abnormalities characteristic of ms and if they are determined to be at high risk of developing clinically definite multiple sclerosis. safety and efficacy in patients with chronic progressive multiple sclerosis has not been evaluated.

İsrail - İbranice - Ministry of Health

rekah pharmaceutical industry ltd, israel - salicylic acid - משחה - salicylic acid 3 % - salicylic acid - salicylic acid - topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including dandruff, keratosis palmaris and plantaris, psoriasis - keratin of scalp, hands, legs and elbows.

İsrail - İbranice - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 150 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.

İsrail - İbranice - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 100 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.